Hutchison MediPharma May IPO within Two Years

Chi-Med plans to spin off its drug development arm, Hutchison MediPharma, within two years, possibly through an IPO on the Nasdaq exchange. According to the company, the offering would be the largest Nasdaq IPO of a China biotech. At the same time, Hutchison MediPharma is seeking a partner for its lead product, HMPL-004, a treatment for ulcerative colitis that recently released positive results from a Phase IIb trial in the US. More details... Stock Symbol: (AIM: HCM)